Free Trial
→ Elon’s Biggest Launch Ever: 15x Bigger Than SpaceX (From InvestorPlace) (Ad)tc pixel
OTCMKTS:SEOVF

Sernova Biotherapeutics 3/19/2026 Earnings Report

Sernova Biotherapeutics logo
$0.13 0.00 (-2.72%)
As of 05/7/2026 10:12 AM Eastern
ProfileEarnings History

Sernova Biotherapeutics EPS Results

Actual EPS
-$0.01
Consensus EPS
-$0.01
Beat/Miss
Missed by -$0.00
One Year Ago EPS
N/A

Sernova Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sernova Biotherapeutics Announcement Details

Quarter
Date
3/19/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Sernova Biotherapeutics' next earnings date is estimated for Thursday, June 11, 2026, based on past reporting schedules.

Conference Call Resources

Sernova Biotherapeutics Earnings Headlines

Sernova Biotherapeutics: Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to ...
March 4, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/67852946-sernova-biotherapeutics-sernova-biotherapeutics-strengthens-balance-sheet-with-dollar-7-1-million-in-financings-plus-net-retirement-of-a-cumulative-dollar-17-mil-296.htm
Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts
November 13, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/sernova-biotherapeutics-closes-first-tranche-120000926.html
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
 |  InvestorPlace (Ad)
Sernova Biotherapeutics Announces Collaboration with Eledon ...
July 11, 2025  |  morningstar.comM
Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes
July 9, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/09/3112555/0/en/sernova-biotherapeutics-announces-collaboration-with-eledon-pharmaceuticals-to-advance-a-potential-functional-cure-for-type-1-diabetes.html
Sernova Biotherapeutics Taps CEO to Be Interim Chair
June 2, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/sernova-biotherapeutics-taps-ceo-to-be-interim-chair-46e2f199
See More Sernova Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sernova Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sernova Biotherapeutics and other key companies, straight to your email.

About Sernova Biotherapeutics

Sernova Biotherapeutics (OTCMKTS:SEOVF) is a clinical‐stage biotechnology company focused on developing and commercializing cell‐based therapeutic technologies for patients with chronic and life‐threatening diseases. Headquartered in London, Ontario, Canada, the firm is advancing an implantable device platform designed to support the long-term survival and function of therapeutic cells. The company’s lead product candidate, known as the Cell Pouch System, is engineered to create a vascularized environment in which transplanted cells can thrive, with an initial emphasis on treating patients with type 1 diabetes.

In its core program, Sernova has initiated a Phase I/II clinical trial evaluating the safety and efficacy of the Cell Pouch System in individuals with type 1 diabetes who require islet cell transplantation. Beyond diabetes, the company is exploring broader applications of its delivery platform, including therapies for hemophilia and other endocrine and metabolic disorders. Preclinical studies have demonstrated the ability of the Cell Pouch to promote cell engraftment and function, positioning Sernova’s technology as a potential alternative to conventional chronic drug administration.

Founded in 2008 and formerly known as Sernova Corp, the company rebranded as Sernova Biotherapeutics in late 2023 to better reflect its evolving pipeline. Sernova conducts its clinical activities across North America and Europe, collaborating with academic and clinical research centers to advance its trials. Leading the organization is Dr. Philip A. Toleikis, Sernova’s founder, president and chief executive officer, who brings more than two decades of experience in regenerative medicine and cell‐based therapy development.

View Sernova Biotherapeutics Profile
Earnings Tools